Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis

Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis

Objective:Patients with type 2 diabetes have an increased tendency to develop hepatosteatosis. The effects of drugs used to treat diabetes on the liver, regardless of the disease, are unknown.The aim of this study was to investigate the effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on...

Full description

Bibliographic Details
Main Authors: Cumali KARATOPRAK, Rukiye KILIÇARSLAN, Mustafa ÇAKIRCA, Sinem AYDIN, Tuba ÖZKAN, Mehmet ZORLU, Muharrem KISKAÇ
Format: Article
Language:English
Published: Galenos Publishing House 2019-10-01
Series:Bezmiâlem Science
Subjects:
di-peptidyl peptidase 4 inhibitors
vildagliptin
portal vein pressure
hepatosteatosis
tip 2 diabetes mellitus
Online Access: http://bezmialemscience.org/archives/archive-detail/article-preview/effects-of-18-month-vildagliptin-treatment-on-port/30625

Internet

http://bezmialemscience.org/archives/archive-detail/article-preview/effects-of-18-month-vildagliptin-treatment-on-port/30625

Similar Items